Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00021749 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia
A Phase 1 study of Chronic Lymphocytic Leukemia and CLL, sponsored by Genta Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 3
- Study locations
NCT00021749: Completed Phase 1 study of Chronic Lymphocytic Leukemia and CLL, sponsored by Genta Incorporated.
NCT00021749 is a Phase 1 study of Chronic Lymphocytic Leukemia and CLL that has completed, run by Genta Incorporated. The registered enrollment target is 40 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (78% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00021749, a Phase 1 study of Chronic Lymphocytic Leukemia and CLL, has completed, sponsored by Genta Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 3
- Study locations
Study Summary
This non-randomized study will test the safety and effectiveness of Genasense in patients with CLL.
Conditions Studied
Interventions
- DRUG Oblimerson sodium, G3139
Study Locations (3)
Texas
- MD Anderson Cancer Center - Houston
- San Antonio Cancer Institute - San Antonio
New York
- Long Island Jewish Medical Center - New Hyde Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2001-01 |
| Phase | Phase 1 |
What the finished NCT00021749 record still lists
NCT00021749 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (78% lower).
The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Oblimerson sodium, G3139 is the first listed.
NCT00021749 reports a single indexed study location in Texas, New York.
Frequently Asked Questions
What is clinical trial NCT00021749 about?
NCT00021749 is a clinical study titled "Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia". This non-randomized study will test the safety and effectiveness of Genasense in patients with CLL.
What is the current status of trial NCT00021749?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2001-01.
What conditions does trial NCT00021749 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, CLL.
What interventions are being tested in trial NCT00021749?
The interventions under investigation include: Oblimerson sodium, G3139 (DRUG).
Who is sponsoring clinical trial NCT00021749?
This trial is sponsored by Genta Incorporated, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00021749 being conducted?
This trial has 3 study locations across New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00021749's enrollment target sits among peer trials
40 115th of 187 higher than 67 of 187 other Chronic Lymphocytic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia